JPMorgan Chase & Co. Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

AbbVie (NYSE:ABBV) had its target price increased by stock analysts at JPMorgan Chase & Co. from $285.00 to $300.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 10.21% from the stock’s previous close.

Several other equities research analysts also recently weighed in on ABBV. Leerink Partners lifted their price target on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Rothschild & Co Redburn boosted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research note on Tuesday. Finally, Citigroup raised their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $276.64.

AbbVie Stock Performance

Shares of AbbVie stock traded up $0.84 on Thursday, reaching $272.20. 4,301,284 shares of the company’s stock were exchanged, compared to its average volume of 6,423,691. The company has a market capitalization of $480.92 billion, a P/E ratio of 76.89, a price-to-earnings-growth ratio of 1.22 and a beta of 0.24. AbbVie has a 52 week low of $190.75 and a 52 week high of $274.94. The firm’s 50-day moving average is $258.27 and its two-hundred day moving average is $235.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business posted $2.97 EPS. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie will post 13.93 EPS for the current fiscal year.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ABBV. Burk Holdings LLC bought a new stake in AbbVie during the second quarter worth $30,000. Abound Financial LLC bought a new position in AbbVie during the 4th quarter valued at $32,000. Merkkuri Wealth Advisors LLC bought a new position in AbbVie during the 1st quarter valued at $34,000. Marquette Asset Management LLC boosted its holdings in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie in the 4th quarter worth $36,000. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. The designations cover colorectal cancer and non-small cell lung cancer. They may accelerate development and regulatory review for telisotuzumab adizutecan, AbbVie’s investigational c-Met-directed antibody-drug conjugate, although they do not guarantee approval or commercial success. AbbVie’s Temab-A Receives Two Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 data for Epkinly could expand AbbVie’s hematologic-cancer opportunity. AbbVie and Genmab said epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly in frontline treatment. AbbVie and Genmab Phase 3 Epkinly Data
• Positive Sentiment: Cantor Fitzgerald raised its price target from $285 to $290 and maintained an “overweight” rating. The target increase reflects continued analyst confidence in AbbVie’s pipeline and earnings outlook. Why Is AbbVie Stock Trending After Hours?

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.